No profile data available.
Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare company in the medication development research industry, based in Salt Lake City, United States, with about 600 full-time employees.
It reported revenue of $74.26 million for fiscal year 2025, up 27.0% from fiscal year 2024, and net income of -$644.76 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $6.30 million, down 57.5% from a year before. United States was its largest region in fiscal year 2025, with 53% of revenue. Its market capitalization was $2.34 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Recursion Pharmaceuticals reported $74.26 million in revenue for fiscal year 2025, up 27.0% from $58.49 million in fiscal year 2024. In Q1 2026 revenue was $6.30 million.
United States: 53% of revenue by region in fiscal year 2025, followed by United Kingdom (47%).
$2.34 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Tango Therapeutics, Inc. (TNGX), AbCellera Biologics Inc. (ABCL), Absci Corporation (ABSI), Evotec SE (EVO).